#Canada #Princeton #Psilocybin #Clinical Research #Optimi Health

Optimi Health Elevates Clinical Research

In an exciting advancement for clinical research in psychedelic therapies, Optimi Health Corp. has announced the production of two new standardized microdose psilocybin products, formulated at 1 mg and 2 mg dosages. These products are set to provide research organizations with the validated, consistent doses crucial for controlled studies. The introduction of these microdose formats marks a significant expansion of Optimi's psilocybin product line, which includes a 5 mg formulation that is already prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme.

Microdosing involves taking low doses of psychedelics to achieve subtle effects without the perceptual alterations that higher doses can induce. Popular microdosing regimens, such as the Fadiman protocol and the Stamets protocol, schedule doses to maximize benefits while minimizing the risk of tolerance. However, many existing microdosing practices rely on dried mushrooms, which can exhibit considerable variability in psilocybin concentration. Optimi's microdose capsules provide a solution by delivering precisely measured doses that researchers can trust.

Dane Stevens, CEO and Co-Founder of Optimi, emphasized the significance of this new product line. He stated, "Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi's capsules deliver naturally derived psilocybin at a validated, consistent dose, fulfilling the requirements of controlled research."

What's pivotal about these products is that Optimi manages the entire production process at its Health Canada-licensed facility in Princeton, British Columbia. From cultivating and harvesting the mushrooms to generating a full-spectrum mushroom extract that serves as the active pharmaceutical ingredient (API), every step occurs in-house. This level of control ensures consistency and quality, positioning Optimi as a leader in regulated psychedelic product manufacturing.

The company's commitment extends beyond merely supplying microdoses. Optimi Health also supplies finished psilocybin and MDMA drug products to various regulated markets worldwide, supporting clinical research and patient access. The company's products are currently accessible to patients in Australia and Canada through special access programs, reflecting Optimi's aim to bridge the gap between cutting-edge scientific research and real-world therapeutic applications.

As the field of psychedelic research continues to grow, the introduction of standardized microdoses represents a critical step forward. Researchers now have access to precise dosing, which can dramatically enhance the reliability of clinical trials aimed at exploring the potential benefits of psilocybin for various mental health conditions.

For further inquiries regarding product supply for clinical trials or special access programs, Optimi Health can be contacted directly via email. Given the rapid evolution of psychedelic therapies, the company's innovative advancements will likely play an essential role in shaping the future of mental health treatment.

About Optimi Health

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on the manufacturing and distribution of GMP-grade psychedelic drugs designed for mental health therapies. With a commitment to quality and consistency, Optimi produces both active pharmaceutical ingredients and finished dosage forms to meet the needs of regulated clinical and therapeutic programs internationally. As the landscape of mental health treatment evolves, Optimi remains dedicated to advancing research and improving patient access to innovative therapies.

For more information, visit Optimi Health or optimi.net.